Alantolactone is a natural product that potently inhibits YAP1/TAZ through promotion of reactive oxygen species accumulation. Issue 10 (6th August 2021)
- Record Type:
- Journal Article
- Title:
- Alantolactone is a natural product that potently inhibits YAP1/TAZ through promotion of reactive oxygen species accumulation. Issue 10 (6th August 2021)
- Main Title:
- Alantolactone is a natural product that potently inhibits YAP1/TAZ through promotion of reactive oxygen species accumulation
- Authors:
- Nakatani, Keisuke
Maehama, Tomohiko
Nishio, Miki
Otani, Junji
Yamaguchi, Keiko
Fukumoto, Miki
Hikasa, Hiroki
Hagiwara, Shinji
Nishina, Hiroshi
Mak, Tak Wah
Honma, Teruki
Kondoh, Yasumitsu
Osada, Hiroyuki
Yoshida, Minoru
Suzuki, Akira - Abstract:
- Abstract: Yes‐associated protein 1 (YAP1) and its paralogue PDZ‐binding motif (TAZ) play pivotal roles in cell proliferation, migration, and invasion, and abnormal activation of these TEAD transcriptional coactivators is found in diverse cancers in humans and mice. Targeting YAP1/TAZ signaling is thus a promising therapeutic avenue but, to date, few selective YAP1/TAZ inhibitors have been effective against cancer cells either in vitro or in vivo. We screened chemical libraries for potent YAP1/TAZ inhibitors using a highly sensitive luciferase reporter system to monitor YAP1/TAZ‐TEAD transcriptional activity in cells. Among 29 049 low‐molecular‐weight compounds screened, we obtained nine hits, and the four of these that were the most effective shared a core structure with the natural product alantolactone (ALT). We also tested 16 other structural derivatives of ALT and found that natural ALT was the most efficient at increasing ROS‐induced LATS kinase activities and thus YAP1/TAZ phosphorylation. Phosphorylated YAP1/TAZ proteins were subject to nuclear exclusion and proteosomic degradation such that the growth of ALT‐treated tumor cells was inhibited both in vitro and in vivo. Our data show for the first time that ALT can be used to target the ROS‐YAP pathway driving tumor cell growth and so could be a potent anticancer drug. Abstract : YAP1 and its paralogue TAZ play pivotal roles in cell proliferation, migration, and invasion, and abnormal activation of these TEADAbstract: Yes‐associated protein 1 (YAP1) and its paralogue PDZ‐binding motif (TAZ) play pivotal roles in cell proliferation, migration, and invasion, and abnormal activation of these TEAD transcriptional coactivators is found in diverse cancers in humans and mice. Targeting YAP1/TAZ signaling is thus a promising therapeutic avenue but, to date, few selective YAP1/TAZ inhibitors have been effective against cancer cells either in vitro or in vivo. We screened chemical libraries for potent YAP1/TAZ inhibitors using a highly sensitive luciferase reporter system to monitor YAP1/TAZ‐TEAD transcriptional activity in cells. Among 29 049 low‐molecular‐weight compounds screened, we obtained nine hits, and the four of these that were the most effective shared a core structure with the natural product alantolactone (ALT). We also tested 16 other structural derivatives of ALT and found that natural ALT was the most efficient at increasing ROS‐induced LATS kinase activities and thus YAP1/TAZ phosphorylation. Phosphorylated YAP1/TAZ proteins were subject to nuclear exclusion and proteosomic degradation such that the growth of ALT‐treated tumor cells was inhibited both in vitro and in vivo. Our data show for the first time that ALT can be used to target the ROS‐YAP pathway driving tumor cell growth and so could be a potent anticancer drug. Abstract : YAP1 and its paralogue TAZ play pivotal roles in cell proliferation, migration, and invasion, and abnormal activation of these TEAD transcriptional coactivators is found in diverse cancers in humans and mice. We screened chemical libraries for potent YAP1/TAZ inhibitors using a highly sensitive luciferase reporter system to monitor YAP1/TAZ‐TEAD transcriptional activity in cells. We found that alantolactone primarily targets the ROS‐YAP pathway driving tumor cell growth and so could be a potent anticancer drug. … (more)
- Is Part Of:
- Cancer science. Volume 112:Issue 10(2021)
- Journal:
- Cancer science
- Issue:
- Volume 112:Issue 10(2021)
- Issue Display:
- Volume 112, Issue 10 (2021)
- Year:
- 2021
- Volume:
- 112
- Issue:
- 10
- Issue Sort Value:
- 2021-0112-0010-0000
- Page Start:
- 4303
- Page End:
- 4316
- Publication Date:
- 2021-08-06
- Subjects:
- alantolactone -- hippo‐YAP pathway -- ROS -- TAZ -- YAP1
Cancer -- Periodicals
Neoplasms -- Periodicals
Research -- Periodicals
Electronic journals
616.994005 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=1347-9032;screen=info;ECOIP ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1349-7006 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cas.15079 ↗
- Languages:
- English
- ISSNs:
- 1347-9032
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3046.603000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 19137.xml